|Last Update: 06/18/13 - 4:00 PM EDT|
|YTD Performance: 18.17%|
|Previous Close: $58.17|
|52 Week Range: $35.99 - $71.56|
|Oustanding Shares: 139,010,175|
|Market Cap: 8,082,051,575|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||11||11||15||13|
|Growth Rate (Year over Year)||-3.70%||-690.91%||-34.46%||41.34%|
Jim Cramer looks at stocks moving on cancer-fighting develompents, in a discussion with Mad Money Research Director Nicole Urken
BMRN price target was raised to $79 as anti-cancer drug BMN-673 was included in the model, said Citigroup.
BMRN was initiated with a Neutral rating, Credit Suisse said. Valuation call, based on a $68 price target.
Jim Cramer discusses hyper growth names with safety in discussion with Mad Money Research Director Nicole Urken
Stocks that defy correction and those ripe for correction.
The slow, steady push higher continues.
Adam Feuerstein, Sr. Columnist for TheStreet, says the BIO CEO Conference is the next big thing in biotech.
It's the bulls' turn to shine.
BMRN was upgraded from Hold to Buy, Stifel Nicolaus said. $67 price target. New products should drive growth and the company is a potential acquisition target.
Adam Feuerstein, senior columnist for TheStreet, says the coming week's J.P. Morgan Healthcare Conference is the next big thing in biotech.